• Home  /
  • Research & Analysis   /
  • Two Top Stories of NYSE: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), TherapeuticsMD, Inc. (NYSE:TXMD)

Two Top Stories of NYSE: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), TherapeuticsMD, Inc. (NYSE:TXMD)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

The shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) started off the last trading session with the price of $2.82 while closing the day with the price of $2.69. The shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Fell -4.95% with the Loss of -0.13 points.

The shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) traded with the day volume of 2.14 Million shares whereas its average trading volume is 593.79 Million.

While analyzing the past performance of the stock we can see that the shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Loss -16.72% in the last week while Falling -22.48% in the last month. Past quarter performance shows the red light with -35.18%. The semi-annual and annual performance shows 4.67% and 78.15% respectively.

Some critical values of the shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to be discussed here are: the beta which shows the value at 1.4 while Average True Range of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) demonstrate the value at 0.16. The weekly and monthly volatility of the shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) are indicated at 7.41% and 4.86%. Also to discuss here is the Relative Strength Index or RSI which is depicted at 20.08.

While studying the financial position of the shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), we can see that the Market capitalization of the company is at 243.5 Million. The shares outstanding for the company is 90.52 Million and the shares float stands at 55.98 Million. The income of the company stand at -18400000 while the sales stand at 0.

Here are some critical ratios for a financial perspective: Earnings Per Share or EPS of the company stand at -0.21, Price to Earnings or P/E is at 0, Price to Sales P/S show the value of 0, the Return on Asset ROA stood at -0.38 and the Return on Equity ROE depicted at -0.405 while Return on Investment ROI is at 0.


TherapeuticsMD, Inc. (NYSE:TXMD)

TherapeuticsMD, Inc. (NYSE:TXMD) started its previous trading session at $5.14 and closed at $5.25 showing a Rise of 1.74 Percent.

The Company traded with an average Volume of 2.02 Million whereas, its Day Volume stood at 2.14 Million.

Looking at the performance of the stock, TherapeuticsMD, Inc. (NYSE:TXMD) Loss -4.02% in the last week in its shares price and -4.02% in the last month. Quarterly performance shows a red of -21.52 Percent while Semi-Annual and Annual performances shows a -19.48 and -24.46 percent respectively.

Beta for TherapeuticsMD, Inc. (NYSE:TXMD) stands at 1.41 while the ATR (average true range) is at 0.25. The Stock’s Weekly and Monthly Volatility is 3.63% and 5.07% respectively showing a RSI value of 45.72.

While studying the financial position of the shares of TherapeuticsMD, Inc. (NYSE:TXMD), we can see that the Market capitalization of the company is at 1.12 Billion. The shares outstanding for the company is 212.72 Million and the shares float stands at 173.28 Million.

The Company generated an income of -76900000 and the sales of 16.8 Million in the Trailing Twelve Months period.

While analyzing the stock from technical aspects, Diluted Earnings per share stands at $-0.38 a share. P/E (price to earnings) and P/S (price to sales) values are 0 and 66.48 respectively.

The Return on Assets stands at -0.575, ROE shows a value of -0.637 and ROI for TherapeuticsMD, Inc. (NYSE:TXMD) is -0.598 as of Trailing Twelve Months period.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a comment